Out-of-Specification HPLC Assay with a Failed System Suitability Run
A quality control laboratory is assaying a 500 mg metformin hydrochloride extended-release tablet by HPLC. The first injection sequence gives an assay result of 92.5% of label claim, with an unspecified impurity at 0.42%. System suitability from that run shows tailing factor 1.9 (limit ≤2.0) and resolution 1.3 (limit ≥1.5). The analyst reruns the same sample preparation and obtains 98.1% assay with tailing 1.1 and resolution 2.0. The batch is due for release, and production pressures the laboratory to report the second result as final. The laboratory has a validated method, a recent column change, and a mobile phase prepared the previous day. The specification for assay is 95.0% to 105.0%, and the unspecified impurity limit is 0.5%.
1. Is the second result valid for release? Explain the regulatory and scientific reasoning.
Read the worked answer
The second result cannot simply be reported as final. The first run failed system suitability because resolution was 1.3, below the required 1.5, so that run is invalid and its assay and impurity results cannot be used for release. However, an invalid run does not automatically validate a passing rerun. The laboratory must conduct an out-of-specification investigation, including a laboratory phase, before repeating the test. Rerunning until a passing result appears is data-integrity misconduct. The second run's system suitability passed, but the investigation must determine whether the first failure was caused by the column, mobile phase, sample preparation, or instrument. The 98.1% result may eventually be acceptable if the root cause is identified and documented as analytical, but release cannot be based on the second injection alone without that investigation.
2. What root causes and corrective actions should the laboratory investigate?
Read the worked answer
The most likely root cause is column performance or equilibration after the recent column change, because resolution failed while tailing was near the limit. The mobile phase prepared the previous day should be checked for pH, composition, degassing, and microbial growth. The analyst should review sample preparation, injection volume, and whether the column was properly equilibrated. System suitability failure should be investigated before any rerun. Corrective actions include re-equilibrating or replacing the column, preparing fresh mobile phase, verifying pH and buffer strength, and documenting the column history. If the impurity at 0.42% is confirmed in a valid run, it remains within the 0.5% limit but should be trended. Training on OOS procedures and second-person review of system suitability would prevent pressure-driven reruns.
3. What should be reported, and how should the batch disposition be decided?
Read the worked answer
The laboratory should report both runs transparently, identify the first as invalid due to system suitability failure, and document the investigation. The batch disposition should be based on valid analytical data from a properly qualified run, not on the higher of two results. If the investigation confirms an analytical root cause and a valid repeat run meets specification, the batch may be released with the investigation and retest data included in the batch record. If the investigation cannot identify an analytical cause, or if the original OOS result is confirmed, the batch should be rejected or further investigated. The impurity result should be evaluated against the limit and trended. Quality assurance, not production, should approve the conclusion, and the release decision must be independent of schedule pressure.